Using plant cells as influenza vaccine substrates.
The reappearance of highly pathogenic avian influenza H5N1 in poultry in 2003, and the subsequent high-fatality zoonoses in Asia, Europe and Africa, has heightened the awareness of a potential pandemic and the need for global vaccine supply. Most manufacturers still use embryonated hens' eggs to produce influenza vaccines, a system that has demonstrated its value throughout six decades. There are, however, some challenges with this approach, both for seasonal and particularly for pandemic vaccine production. This review highlights some of these challenges and describes emerging alternative production platforms with the potential to deliver safe and effective vaccines to the global market in a timely fashion. A particular emphasis of this review will be on the production of recombinant influenza vaccines using transient plant expression systems.
Chichester
Jessica A
JA
Fraunhofer USA Center for Molecular Biotechnology, 9 Innovation Way, Suite 200, Newark, DE 19711, USA. jchichester@fraunhofer-cmb.org
Haaheim
Lars R
LR
Yusibov
Vidadi
V
D001709:Biotechnology / Q000379:methods*; D018929:Cell Culture Techniques / Q000379:methods; D004345:Drug Industry / Q000379:methods*; D006801:Humans; D007252:Influenza Vaccines / Q000235:genetics*; D010944:Plants / Q000235:genetics*; D014614:Vaccines, Synthetic / Q000235:genetics
D007252:Influenza Vaccines; D014614:Vaccines, Synthetic